07:00 , Jun 16, 2014 |  BC Week In Review  |  Clinical News

OCU100 regulatory update

Ocugen said FDA granted Orphan Drug designation to OCU100 to treat retinitis pigmentosa. The company plans to start Phase I testing for OCU100, a recombinant PC4 and SFRS1-interacting protein ( PSIP1 ; LEDGF ; p75;...
07:00 , Jun 16, 2014 |  BC Week In Review  |  Company News

Ocugen, University of Colorado deal

The university granted Ocugen exclusive, worldwide rights to assets related to PC4 and SFRS1-interacting protein ( PSIP1 ; LEDGF ; p75; LEDGF/p75 ), including preclinical compounds OCU100 and OCU200 . OCU100 is a recombinant LEDGF...
07:00 , Apr 17, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cervical cancer PC4 and SFRS1-interacting protein (PSIP1; LEDGF; p75; LEDGF/p75) Studies in cell culture and patient samples suggest inhibiting LEDGF expression could help treat HPV+...
07:00 , May 30, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Ophthalmic disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Ophthalmic disease Age-related macular degeneration (AMD); retinitis PC4 and SFRS1-interacting protein (PSIP1; LEDGF; p75; LEDGF/p75) Cell culture and rat studies suggest the...
07:00 , Sep 27, 2010 |  BC Week In Review  |  Company News

Pfizer, Catholic University Leuven deal

The university granted Pfizer exclusive, worldwide rights to develop and commercialize ledgins to treat HIV infection. Ledgins are compounds which inhibit the interaction between viral integrase and the cellular protein PC4 and SFRS1-interacting protein (...
07:00 , Apr 30, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

This week in therapeutics Indication Target/marker/ pathway Summary Licensing status Publication and contact information Neurology Alzheimer's disease (AD) PC4 and SFRS1 interacting protein 1 (PSIP1; p75) Studies in cell culture and in mice suggest that...
07:00 , Mar 12, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Pulmonary disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Pulmonary disease Cystic fibrosis (CF) Interferon-related developmental regulator 1 (IFRD1; PC4) Genomics analyses, cellular assays and mouse studies suggest that targeting IFRD1...
08:00 , Mar 1, 1999 |  BC Week In Review  |  Clinical News

V.I. Technologies preclinical data

VITX presented data showing that its Pc4 system was able to clear red blood cells of HIV, BVDV (a model for hepatitis C virus) and the parasites that cause malaria and Chagas disease to below...